Entrada Therapeutics (TRDA) News Today

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) insider Natarajan Sethuraman sold 600 shares of the company's stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $18.00, for a total value of $10,800.00. Following the transaction, the insider now directly owns 189,452 shares of the company's stock, valued at approximately $3,410,136. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Entrada Therapeutics (NASDAQ:TRDA) Trading Down 3.6%

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) CFO Kory James Wentworth sold 1,758 shares of the firm's stock in a transaction on Monday, July 8th. The shares were sold at an average price of $14.95, for a total value of $26,282.10. Following the sale, the chief financial officer now directly owns 81,412 shares of the company's stock, valued at $1,217,109.40. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Equities researchers at HC Wainwright increased their Q2 2024 earnings per share estimates for shares of Entrada Therapeutics in a research report issued on Tuesday, June 25th. HC Wainwright analyst R. Selvaraju now anticipates that the com

Entrada Therapeutics (NASDAQ:TRDA) Shares Up 4.1%

HC Wainwright lowered their price objective on Entrada Therapeutics from $20.00 to $18.00 and set a "buy" rating for the company in a research report on Tuesday.

Entrada Therapeutics (NASDAQ:TRDA) Shares Gap Down to $16.45

Entrada Therapeutics (NASDAQ:TRDA) Sees Unusually-High Trading Volume

72 Investment Holdings LLC reduced its position in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 66.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 172,600 shares of the company's stock after selling 336,423 shares du

Entrada Therapeutics (NASDAQ:TRDA) Trading 7% Higher

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) insider Natarajan Sethuraman sold 1,000 shares of Entrada Therapeutics stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $15.00, for a total transaction of $15,000.00. Following the completion of the sale, the insider now owns 208,032 shares in the company, valued at $3,120,480. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim acquired 2,276 shares of the business's stock in a transaction dated Wednesday, May 8th. The shares were acquired at an average cost of $14.04 per share, with a total value of $31,955.04. Following the acquisition, the director now directly owns 65,212 shares of the company's stock, valued at approximately $915,576.48. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim acquired 2,600 shares of Entrada Therapeutics stock in a transaction that occurred on Monday, April 8th. The shares were bought at an average price of $13.57 per share, for a total transaction of $35,282.00. Following the transaction, the director now owns 62,936 shares of the company's stock, valued at approximately $854,041.52. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim bought 1,512 shares of Entrada Therapeutics stock in a transaction on Thursday, March 28th. The stock was acquired at an average cost of $13.75 per share, for a total transaction of $20,790.00. Following the acquisition, the director now owns 60,336 shares in the company, valued at approximately $829,620. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim bought 3,180 shares of Entrada Therapeutics stock in a transaction dated Monday, March 25th. The stock was acquired at an average cost of $13.36 per share, with a total value of $42,484.80. Following the completion of the acquisition, the director now owns 56,074 shares of the company's stock, valued at $749,148.64. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) Director Peter S. Kim bought 900 shares of the firm's stock in a transaction dated Tuesday, March 19th. The shares were acquired at an average cost of $12.66 per share, with a total value of $11,394.00. Following the completion of the transaction, the director now owns 47,944 shares of the company's stock, valued at $606,971.04. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Investment analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for Entrada Therapeutics in a note issued to investors on Monday, March 18th. HC Wainwright analyst R. Selvaraju forecasts that the company will ea

HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Entrada Therapeutics in a report on Monday.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Investment analysts at William Blair lowered their Q1 2024 earnings per share estimates for Entrada Therapeutics in a research report issued to clients and investors on Wednesday, March 13th. William Blair analyst M. Minter now forecasts th